Posted by Michael Wonder on 27 Sep 2021
Canadian cancer patients have new affordable treatment option
27 September 2021 - Apobiologix expanded its leadership in Canada's biosimilar market with the approval of its first therapeutic treatment, Bambevi.
The company, a pioneer and leader in oncology biosimilars in Canada, recently received approval from Health Canada for its first therapeutic product.
Bambevi ( bevacizumab) is used in combination with chemotherapy to treat specific types of colorectal, lung, brain and ovarian cancer.
